Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

The Company expects to submit a New Drug Application to the Food and Drug Administration in the third quarter of 2025.

Corcept attributed the revenue shortfall to supply chain issues at its specialty pharmacy vendor early in the quarter, which impacted its ability to fulfill a surge in demand. The company noted that ...

On CORT's first-quarter 2025 earnings call, investors are likely to focus on the sales performance of its Cushing's syndrome drug, Korlym.

We recently published a list of Billionaire Jim Simons’ RenTech’s 10 Small-Cap Stock Picks with Huge Upside Potential.

The firm said it based the decision on the announcement of successful Phase 3 ROSELLA study results in platinum-resistant ovarian cancer. While we acknowledge the potential of Corcept Therapeutics ...

in combination with nab-paclitaxel for treating patients with platinum-resistant ovarian cancer, met its primary endpoint of improved progression-free survival (PFS). Corcept plans to submit a new ...

The ROSELLA study evaluating Corcept's relacorilant plus nab-paclitaxel for treating patients with platinum-resistant ovarian cancer meets the primary endpoint. Corcept (CORT) was a big mover last ...

One of the losers of today's trading session was Corcept Therapeutics ... which is in phase III clinical trial to treat platinum-resistant ovarian tumors; treatment for adrenal cancer and cortisol ...